425
J.P. Morgan Healthcare Conference
Investor Presentation
January 12, 2015
Filed by Wright Medical Group, Inc.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Wright Medical Group, Inc.
Commission File No.: 001-35823

Cautionary Note Regarding Forward-Looking Statements       
2
This
presentation
includes
forward-looking
statements.
These
forward-looking
statements
generally
can
be
identified
by
the
use
of
words
such
as
“anticipate,”
“expect,”
“plan,”
“could,”
“may,”
“will,”
“believe,”
“estimate,”
“forecast,”
“goal,”
“project,”
and
other
words
of
similar
meaning.
Forward-looking
statements
in
this
presentation
include,
but
are
not
limited
to,
statements
about
our
outlook
for
our
expected
financial
results
for
the
fourth
quarter
and
full
year
2014;
statements
about
the
approvable
status
and
anticipated
final
PMA
approval
of
Augment
®
Bone
Graft
and
the
anticipated
positive
effects
of
such;
and
statements
about
the
timing
and
anticipated
benefits
of
the
previously
announced
merger
with
Tornier.
Each
forward-looking
statement
contained
in
this
presentation
is
subject
to
risks
and
uncertainties
that
could
cause
actual
results
to
differ
materially
from
those
expressed
or
implied
by
such
statement.
Applicable
risks
and
uncertainties
include,
among
others,
quarter
end
closing
adjustments
that
could
cause
actual
financial
results
to
differ
from
anticipated
results;
uncertainties
as
to
the
timing
of
the
Tornier
transaction;
uncertainties
as
to
whether
Tornier
shareholders
and
Wright
shareholders
will
approve
the
transaction;
the
risk
that
competing
offers
will
be
made;
the
possibility
that
various
closing
conditions
for
the
transaction
may
not
be
satisfied
or
waived,
including
that
a
governmental
entity
may
prohibit,
delay
or
refuse
to
grant
approval
for
the
consummation
of
the
transaction,
or
the
terms
of
such
approval;
the
effects
of
disruption
from
the
transaction
making
it
more
difficult
to
maintain
relationships
with
employees,
customers,
vendors
and
other
business
partners;
the
risk
that
shareholder
litigation
in
connection
with
the
transaction
may
result
in
significant
costs
of
defense,
indemnification
and
liability;
other
business
effects,
including
the
effects
of
industry,
economic
or
political
conditions
outside
of
Wright’s
or
Tornier’s
control;
the
failure
to
realize
synergies
and
cost-savings
from
the
transaction
or
delay
in
realization
thereof;
the
businesses
of
Wright
and
Tornier
may
not
be
combined
successfully,
or
such
combination
may
take
longer,
be
more
difficult,
time-consuming
or
costly
to
accomplish
than
expected;
operating
costs
and
business
disruption
following
completion
of
the
transaction,
including
adverse
effects
on
employee
retention
and
on
Wright’s
and
Tornier’s
respective
business
relationships
with
third
parties;
transaction
costs;
actual
or
contingent
liabilities;
the
adequacy
of
the
combined
company’s
capital
resources;
failure
or
delay
in
ultimately
obtaining
FDA
approval
of
Wright’s
Augment
®
Bone
Graft
for
commercial
sale
in
the
United
States,
failure
to
achieve
the
anticipated
benefits
from
approval
of
Augment
®
Bone
Graft,
and
the
risks
identified
under
the
heading
“Risk
Factors”
in
Wright’s
Annual
Report
on
Form
10-K,
filed
with
the
SEC
on
February
27,
2014,
and
Tornier’s
Annual
Report
on
Form
10-K,
filed
with
the
SEC
on
February
21,
2014,
as
well
as
both
companies’
subsequent
Quarterly
Reports
on
Form
10-Q
and
other
information
filed
by
each
company
with
the
SEC.
Investors
should
not
place
considerable
reliance
on
the
forward-looking
statements
contained
in
this
presentation.
You
are
encouraged
to
read
Wright’s
and
Tornier’s
filings
with
the
SEC,
available
at
www.sec.gov,
for
a
discussion
of
these
and
other
risks
and
uncertainties.
The
forward-looking
statements
in
this
presentation
speak
only
as
of
the
date
of
this
release,
and
Wright
undertakes
no
obligation
to
update
or
revise
any
of
these
statements.
Wright’s
business
is
subject
to
substantial
risks
and
uncertainties,
including
those
referenced
above.
Investors,
potential
investors,
and
others
should
give
careful
consideration
to
these
risks
and
uncertainties.

Wright
and
Tornier
use
non-GAAP
financial
measures,
including
EBITDA,
as
adjusted.
Their
respective
management
teams
believe
that
the
presentation
of
these
measures
provides
useful
information
to
investors
and
that
these
measures
may
assist
investors
in
evaluating
their
respective
company’s
operations,
period
over
period.
EBITDA
is
calculated
by
adding
back
to
net
income
charges
for
interest,
income
taxes
and
depreciation
and
amortization
expenses.
While
it
is
not
possible
to
reconcile
the
adjusted
EBITDA
forecast
in
this
presentation
to
the
nearest
metric
under
U.S.
generally
accepted
accounting
principles
(GAAP)
of
the
combined
business
without
unreasonable
effort,
the
adjusted
EBITDA
forecast
excludes
non-cash
stock
based
compensation
expense
and
non-operating
income
and
expense,
as
well
as
the
expected
impact
of
such
items
as
transaction
and
transition
costs,
impacts
from
the
sale
of
Wright’s
OrthoRecon
business
and
costs
associated
with
distributor
conversions
and
non-competes,
all
of
which
may
be
highly
variable,
difficult
to
predict
and
of
a
size
that
could
have
substantial
impact
on
the
combined
company’s
reported
results
of
operations
for
a
period.
Investors
should
consider
these
non-
GAAP
measures
only
as
a
supplement
to,
not
as
a
substitute
for
or
as
superior
to,
measures
of
financial
performance
prepared
in
accordance
with
GAAP.
Note on Non-GAAP Financial Measures
3

In
connection
with
the
proposed
merger,
Tornier
has
filed
with
the
U.S.
Securities
and
Exchange
Commission
(SEC)
a
registration
statement
on
Form
S-4
that
includes
a
preliminary
joint
proxy
statement
of
Wright
and
Tornier
that
also
constitutes
a
preliminary
prospectus
of
Tornier.
The
registration
statement
is
not
complete
and
will
be
further
amended.
Wright
and
Tornier
will
make
the
final
joint
proxy
statement/prospectus
available
to
their
respective
shareholders.
Investors
are
urged
to
read
the
final
joint
proxy
statement/prospectus
when
it
becomes
available,
because
it
will
contain
important
information.
The
registration
statement,
definitive
joint
proxy
statement/prospectus
and
other
documents
filed
by
Tornier
and
Wright
with
the
SEC
will
be
available
free
of
charge
at
the
SEC’s
website
(www.sec.gov)
and
from
Tornier
and
Wright.
Requests
for
copies
of
the
joint
proxy
statement/prospectus
and
other
documents
filed
by
Wright
with
the
SEC
may
be
made
by
contacting
Julie
D.
Tracy,
Senior
Vice
President
and
Chief
Communications
Officer
by
phone
at
(901)
290-5817
or
by
email
at
julie.tracy@wmt.com,
and
request
for
copies
of
the
joint
proxy
statement/prospectus
and
other
documents
filed
by
Tornier
may
be
made
by
contacting
Shawn
McCormick,
Chief Financial
Officer by phone at (952) 426-7646 or by email at shawn.mccormick@tornier.com.
Wright,
Tornier,
their
respective
directors,
executive
officers
and
employees
may
be
deemed
to
be
participants
in
the
solicitation
of
proxies
from
Wright’s
and
Tornier’s
respective
shareholders
in
connection
with
the
proposed
transaction.
Information
about
the
directors
and
executive
officers
of
Wright
and
their
ownership
of
Wright
stock
is
set
forth
in
Wright’s
annual
report
on
Form
10-K
for
the
fiscal
year
ended
December
31,
2013,
which
was
filed
with
the
SEC
on
February
27,
2014
and
its
proxy
statement
for
its
2014
annual
meeting
of
stockholders,
which
was
filed
with
the
SEC
on
March
31,
2014.
Information
regarding
Tornier’s
directors
and
executive
officers
is
contained
in
Tornier’s
annual
report
on
Form
10-K
for
the
fiscal
year
ended
December
29,
2013,
which
was
filed
with
the
SEC
on
February
21,
2014,
and
its
proxy
statement
for
its
2014
annual
general
meeting
of
shareholders,
which
was
filed
with
the
SEC
on
May
16,
2014.
These
documents
can
be
obtained
free
of
charge
from
the
sources
indicated
above.
Certain
directors,
executive
officers
and
employees
of
Wright
and
Tornier
may
have
direct
or
indirect
interest
in
the
transaction
due
to
securities
holdings,
vesting
of
equity
awards
and
rights
to
severance
payments.
Additional
information
regarding
the
participants
in
the
solicitation
of
Wright and
Tornier shareholders will be included in the joint proxy statement/prospectus.
Important Additional Information and Where To Find It
4

Wright Medical Group, Inc. Announces Preliminary Fourth
Quarter and Full Year 2014 Revenue
•
Full year 2014 sales expected to increase ~23% to $298M
•
Gross margin for 4Q’14 expected to be ~77%
•
U.S. foot and ankle business grew ~39% as reported, up significantly from 28%
in 3Q’14
–
U.S. foot and ankle grew ~16.5% pro forma same sales day basis in 4Q’14, up from
~11.5% in 3Q’14
•
Global total ankle growth expected to be ~38% for 4Q’14, driven primarily by
ongoing launch of INFINITY
®
total ankle 
•
Achieved U.S. sales force productivity goal of exiting 2014 at over $1M per rep 
•
Some progress in increasing visibility into the international supply chain
–
Continued to experience some negative impact in distributor markets while direct
markets performed well
•
Total company growth rate negatively impacted by softness in Upper Extremity
and Biologics business, which is expected to be addressed by pending merger
with Tornier and anticipated final FDA approval of Augment
®
Bone Graft
Continue to focus on improving execution
5

The New Wright Medical:
Global Leader in Extremities-Biologics
6
Global
Extremities-
Biologics
market
~$8B
Wright Medical
position in
Extremities market
post Tornier merger
Wright Medical
growth rate
vs. the market
#1
~2X

Agenda
Strong Performance Record
Augment
®
Approval:  A Game Changer
Pending Transaction Creates Premier
High-Growth Extremities-Biologics Company
The Future:  Outperforming
in Growth Markets
7

Entering a New Growth Era
2012
2014
Future
2011
Multiple markets,  
slow growth
Repositioned as   
high growth, pure
play in Extremities
Transformational merger,
global powerhouse in
Extremities-Biologics
8

Strategy We Have Been Executing
Global leader
in
Extremities
On track to meet all our goals
Improve sales force productivity
Optimize customer conversion
process
International expansion
World class supply chain
(cost & inventory)
Pricing
Targeted M&A
Leverage corporate costs
Leverage U.S. sales and
marketing investments
Execute an effective compliance program and
continue to successfully execute CIA
=  2014 Vital Few Initiative
1.
Accelerate
Global
Revenue
Growth
2.
Improve
Gross
Margin and
Inventory
3.
Improve
EBITDA
Key Priorities
9

Strong Record of Execution
10
Transformational Initiatives
Transitioned U.S. Foot & Ankle sales force to 80+% direct
Expanded global distribution network with 2 acquisitions in Europe
-
WG Healthcare (United Kingdom)
-
Biotech International (France)
Expanded Extremities product / technology portfolio with 2 U.S. acquisitions
-
Solana Surgical
-
OrthoPro
Divested slow growing OrthoRecon business
Acquired
breakthrough
Biologics
platform
and
pipeline
–
Augment
®
Bone
Graft
-
BioMimetic Therapeutics
Received approvable letter from FDA for Augment
®
Bone Graft

RESULTS:
Focused on Higher Growth Segments of the
Orthopedics Market
11
Source:  2014 iData Research Inc., 2013 Millennium Research Group, 2012 Life Science Intelligence, Management Estimates
10%
7-8%
7%
8-9%
6%
3-4%
3%
2-3%
Foot &
Ankle
Sports
Medicine
Biologics
Upper
Extremities
Trauma
Knee
Spine
Hip
Wright Medical focus
Tornier

RESULTS:
Created Extremities Pure Play with Strong Momentum
12
Primary Focus: Foot & Ankle
(Breakdown of 2014 Sales*)
Growth in line with goals
Strong Sales Momentum
(Continuing Operations)
* Preliminary 2014 revenue, unaudited
$
214M
$
242M
$298M*
2012
2013
2014E*
Foot &
Ankle
Upper
Extremity
Biologics
Other
66%
22%
3%
~20%
CAGR
9%

Agenda
13
Strong Performance Record
Augment
®
Approval:  A Game Changer
Pending Transaction Creates Premier 
High-Growth Extremities-Biologics Company
The Future:  Outperforming
in Growth Markets

Augment
®
Bone Graft –
A Breakthrough Product
14
•
First clinically proven, cost-effective alternative
to autograft for ankle and/or hindfoot fusion indications
•
Demonstrates equivalent safety & efficacy with less pain
•
Only synthetic growth factor to market in last 10 years
•
Bone repair
•
Soft tissue indications                                         
(tennis elbow & rotator cuff repair)
•
Recombinant human platelet-derived growth factor   
(rh-PDGF) stimulates bone formation
•
Provides a scaffold for new bone growth
•
Avoids unwanted bone formation in surrounding tissues
observed with BMP-based products
Unique
Solution
Breakthrough
Biologic
Platform for
Future
Growth

Augment
®
Delivers Unmatched Advantages
Augment
®
Bone Graft
Bone
Morphogenetic
Protein (BMP)
Stem
Cells
Demineralized
Bone Matrix
(DBM)
FDA approvable for ankle and/or
hindfoot fusion indications
YES
Level I evidence
YES
Demonstrated safety
YES
?
Reliable / consistent quality
YES
?
?
Available off-the-shelf
YES
Cost effective
(relative to autograft)
YES
15

Augment
®
–
A High Potential Platform Technology
16
Bone
Soft Tissue
Market potential (US)
$300M
Market potential (US)
$1B+
•
Ankle Fusion
•
Hindfoot Fusion
•
Chronic
Tendinopathy
(Tennis Elbow)
•
Rotator Cuff
Repair
1
st
Target
Market
•
Two pre-approval facility inspections indicated necessary by
FDA
for
final
Augment
®
approval
•
One inspection complete with no 483 by inspectors; one
inspection in process. Final audit reports pending.
•
Based
on
this,
final
FDA
approval
for
Augment
®
could
potentially
come as early as late 1Q 2015
Future
rh-PDGF
Clinical
Study
Opportunities

Agenda
17
Strong Performance Record
Augment
®
Approval:  A Game Changer
Pending Transaction Creates Premier 
High-Growth Extremities-Biologics Company
The Future:  Outperforming
in Growth Markets

Transaction Overview
•
All stock –
combined equity value of ~$3.3B at announcement
–
combined entity will be incorporated in the Netherlands
–
combined company ownership:  52% Wright / 48% Tornier
•
Transaction is subject to customary closing conditions
–
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended
–
Wright and Tornier shareholder approval
•
Expected to close in first half of 2015
18

Tornier at A Glance
19
•
Extremities company with leadership
position in Upper Extremities
•
NASDAQ: TRNX
•
HQ in Netherlands; operations run out of
U.S., France and Ireland
•
2014E revenue*:  ~$345M
•
Products sold in 45 countries
–
~42% of revenue outside U.S.
•
1,076 employees globally
Aequalis Ascend
Flex Shoulder System
Latitude EV Elbow
Prosthesis
Salto Talaris Total
Ankle Prosthesis
CannuLink Intraosseous
Fixation System
Primary Focus:  Upper Extremity
(Breakdown of 2014 Sales*)
* Preliminary 2014 revenue, unaudited
Sports Med
& Biologics
Upper
Extremity
62%
17%
17%
4%
Lower
Extremity
Large
Joint

ADVANTAGE #1
Combination Creates Most Comprehensive
Upper and Lower Extremity Product Portfolio
20
* Preliminary 2014 revenue, unaudited
9%
of revenue*
62%
of revenue*
66%
of revenue*
17%
of revenue*
Complementary Product
Portfolios
Market leading
positions
in high-growth
markets
Upper Extremities
Lower Extremities

ADVANTAGE #2
Combining Two Innovative Companies Enhances
Future Growth Prospects
21
INFINITY
®
Total Ankle
Replacement System
Recent
Product
Launches
PRO-TOE
®
offering for Hammertoe
correction
Recent
Product
Launches
Aequalis
Ascend Flex
convertible shoulder
platform
Phantom Fiber
high strength
resorbable suture
Reverse
Threaded
Baseplate
Dedicated R&D will power innovation across combined portfolio

ADVANTAGE #3
Accelerates Growth Opportunities in Three Large,
Fast Growing Markets
22
Augment
®
Bone Graft launch;
Cross-sell Biologics across
expanded Extremities portfolio
Leverage scale across
geographies and categories
Expanded Opportunities
Wright Medical enters
Upper Extremities market with
leadership position in shoulder
2014
2018
Market Growth
(2014
-2018 CAGR)
Upper
Extremity
Lower
Extremity
Biologics
~$7.9B
$5.5B
8-9%
8-10%
5-6%

ADVANTAGE
#4
Creates Mid-Size Growth Company with Stronger
Financial Profile
23
Scale and scope to accelerate path to profitability
Once integrated:        
Solid Financial Profile
*
Excludes
Augment
®
Bone
Graft
Upper
Extremity
Lower
Extremity
Biologics &
Sports Med
Large Joints
& Other
~$298M
~$345M
Combined Sales
$600M+
37%
Upper
Extremity
40%
Lower
Extremity
12%
Bio*
11%
Lg Joints
Revenue Breakdown
(Preliminary 2014 revenue, unaudited)
•
Mid-teens revenue growth
•
High 70s% gross margin
•
Adj. EBITDA margins
approaching 20% in
3-4 years
•
Annual cost synergies of
$40M-$45M by year 3
•
Accretive to combined
adj.
EBITDA
in
2
nd
full
year
post merger

Unique Positioning Will Continue to Sets Us Apart
V I S I O N
Premier High-Growth Extremities-Biologics Company
Dedicated to serving the needs of specialty surgeons
24
SPECIALIZED
SALESFORCES
TECHNOLOGY
LEADER
GLOBAL
FOOTPRINT

Agenda
25
Strong Performance Record
Augment
®
Approval:  A Game Changer
Pending Transaction Creates Premier 
High-Growth Extremities-Biologics Company
The Future:  Outperforming
in Growth Markets

Longer Term –
Continue to Execute Proven Strategy
26
Completely focused:
Extremities-Biologics technology leader
1
Specialized sales forces:
Drive productivity
2
International expansion:
Key market focus, drive adoption
3
New product launches: 
Augment
®
breakthrough product
4
Time
$
Sustainable, high-growth
Extremities market growing
in 8-10% range

Priorities Next 1-2 years
Close merger with Tornier
–
anticipated 1
st
Half of 2015
Ensure smooth integration
–
integration planning is underway
Continue to execute our operating initiatives
–
including sales productivity, new product
launches, medical education
Launch Augment
®
Bone Graft in U.S.
–
anticipated 1
st
Half of 2015
27

28
A CLOSER LOOK AT KEY INITIATIVES
Strong Pipeline of New Product Introductions
28
AUGMENT
®
Bone Graft
•
Proven therapeutic option
•
$300M  U.S. market opportunity
•
Pending FDA approval
2014
2015
2016
INFINITY
®
Total Ankle System
•
Third generation design
•
Further penetrate end-stage ankle
arthritis market opportunity
SIMPLICITI™
•
Will be first minimally invasive shoulder
option in U.S.
•
$200M-$250M market opportunity
In rollout
2017
Launch Date
INVISION™
Revision System
•
Physician testing anticipated in 2015
•
Pending FDA clearance

A CLOSER LOOK AT MERGER:
Clear Line of Sight to Deliver Cost Synergies from Merger
•
Public company expenses
•
Overlapping support functions
•
Overlapping systems
•
Vendor consolidation
•
Process improvement
Key Synergy Areas
Year 3
Annual Cost
Synergies:
$40M-$45M
29

Advancing Toward Our Goals
30
Adj. EBITDA margin
Gross Margin
Sales growth
Mid teens
Adj. EBITDA margins approaching
20% in 3 to 4 years
Goals
Once Integrated With Tornier
High 70s% range

IN SUMMARY
The New Wright Medical: Global Leader in Extremities
31
Solid Performance Record
Augment
®
Approval:
A Game Changer
Pending Transaction
Creates Premier Extremities-
Biologics Company
The Future: Outperforming
in Growth Markets
•
Unmatched capabilities,
unique mid-cap growth asset
•
Built market leader
•
Multiple growth drivers,
accelerated path to profitability
•
High potential platform technology

J.P. Morgan Healthcare Conference
Investor Presentation
January 12, 2015